What is IgA nephropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is IgA Nephropathy?

IgA nephropathy (IgAN), also known as Berger's disease, is the most common primary immune-mediated glomerular disease worldwide, characterized by the deposition of IgA-dominant immune complexes in the glomerular mesangium, leading to glomerular inflammation, scarring, and progressive kidney disease. 1

Pathophysiology

The disease develops through a specific pathogenic mechanism:

  • Abnormal IgA1 production: Patients produce polymeric, undergalactosylated IgA1 molecules that form immune complexes 2, 3
  • Mesangial deposition: These IgA-containing immune complexes deposit in the glomerular mesangium, the definitive diagnostic feature of the disease 4
  • Glomerular injury: The deposits trigger mesangial cell proliferation, inflammation, and eventual glomerulosclerosis 1
  • Receptor involvement: Functional abnormalities of IgA receptors (CD89 on myeloid cells and CD71 on mesangial cells) facilitate complex formation and mesangial trapping 2, 3

Clinical Presentation

IgAN presents with variable manifestations, typically in younger adults (mean age 34-45 years) 1:

  • Asymptomatic microscopic hematuria: Approximately 60% of cases are detected incidentally with hematuria or proteinuria on routine urinalysis 1
  • Episodic gross hematuria: Occurs in 40-50% of patients, characteristically following upper respiratory infections (synpharyngitic hematuria) 4, 1
  • Nephritic syndrome: The typical presentation pattern with hematuria, proteinuria, and variable degrees of kidney dysfunction 1
  • Nephrotic syndrome: Less common, occurring in <5% of cases 1
  • Rapidly progressive glomerulonephritis: Rare presentation (<5%) with extensive crescent formation (usually >50% of glomeruli) and rapid kidney function decline 5, 1

Diagnosis

The diagnosis requires kidney biopsy demonstrating IgA-dominant or co-dominant immune deposits in the glomerular mesangium 4:

  • Biopsy indication: Adults with suspected IgAN and proteinuria ≥0.5 g/day should undergo kidney biopsy 1
  • Immunofluorescence: Shows mesangial IgA deposits as the dominant or co-dominant immunoglobulin 4
  • Electron microscopy: Reveals electron-dense deposits in the mesangium, often with C3 co-deposition 4
  • Exclusion of secondary causes: Must rule out IgA vasculitis, infection-related glomerulonephritis, cirrhosis, inflammatory bowel disease, celiac disease, and autoimmune diseases 4, 1

Prognosis

IgAN is not a benign disease—up to 50% of patients develop kidney failure within 10 years of diagnosis, and 20-40% progress to end-stage renal disease within 5-25 years 1, 6:

  • Clinical risk factors: Elevated serum creatinine at presentation, uncontrolled hypertension, and persistent proteinuria >1 g/day predict progression 4, 6
  • Histologic predictors: Glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescent formation, and severity of tubulointerstitial lesions correlate with worse outcomes 6
  • Risk stratification tools: The MEST-C scoring system (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis, crescents) and International IgAN Prediction Tool provide prognostic information 5

Epidemiology

  • Most common primary glomerulonephritis: Affects an estimated 198,887 to 208,184 persons in the US 1
  • Geographic variation: Highest incidence in East Asia 1
  • Demographics: Predominantly affects young males 6
  • Burden of disease: Accounts for 20-25% of prevalent kidney failure cases in most registries 5

References

Research

New insights in the pathogenesis of IgA nephropathy.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005

Guideline

Diagnosing and Managing IgA Nephropathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical features and natural history of IgA nephropathy.

Annales de medecine interne, 1999

Related Questions

What are the causes of IgA (Immunoglobulin A) nephropathy?
How should chronic glomerulonephritis be evaluated and managed in patients presenting with persistent hematuria, proteinuria ≥300 mg/day, reduced glomerular filtration rate, or hypertension?
What is IgA (Immunoglobulin A) nephropathy?
How should IgA nephropathy be diagnosed and managed, including blood pressure targets, proteinuria goals, and the use of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), corticosteroids, cyclophosphamide, or mycophenolate mofetil?
Can apixaban be used in pulmonary hypertension, and if so, what are the appropriate indications, dosing, and contraindications?
In a 38‑week pregnancy with reduced fetal movements, a non‑reactive cardiotocogram and a lacunar placenta, is it appropriate to assess the middle cerebral artery (MCA) to umbilical artery (UA) Doppler ratio (cerebro‑placental ratio, CPR) to consider continuing the pregnancy to term, both at 37 weeks + 4 days and now at 38 weeks + 2 days, and should the placental lacunae be re‑evaluated for progression?
What is the normal hepatic echotexture on abdominal ultrasound and how do variations in echogenicity indicate liver pathology?
What is the recommended first‑line treatment for an adult with mild multilevel degenerative spondylosis presenting with modest back pain, occasional stiffness, and no neurological deficits?
Can rosuvastatin be prescribed to a patient with myasthenia gravis?
What methylphenidate dosing schedule is appropriate for a healthy 15‑year‑old adolescent with excessive daytime sleepiness who is not a candidate for modafinil?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.